The investigation of glaucoma-related cross-linking proteins, such as lysyl oxidase (LOX)/lysyl oxidase-like 1 (LOXL1), tissue trans-glutaminase (TG2), and advanced glycation end products, will allow corneal gene therapy to be further developed into a promising treatment of glaucoma. The gene discussed is LOX; the disease is glaucoma.